Dr. Kerry Rogers is an Assistant Professor in the Division of Hematology at The Ohio State University and specializes in Chronic Lymphocytic Leukemia (CLL) and Hairy Cell Leukemia (HCL). She is board certified in Internal Medicine as well as both Hematology and Medical Oncology. Dr. Rogers has expertise in therapies for CLL and in addition to caring for patients with CLL and HCL in clinic, she is the principal investigator on several clinical trials studying chemotherapy-free combination regimens for CLL utilizing currently approved or novel agents. These focus on strategies for time-limited treatment or elimination of molecular resistance. She has completed several retrospectives studies examining the effects of the first-in-class BTK inhibitor, ibrutinib. She actively involved in research on targeted agents in HCL. Her other research interests include complications of targeted therapy for CLL, management of Richter’s syndrome, and autoimmune cytopenias.